New Decision Pathway Issued for Managing Patients with Irregular Heartbeat on Anticoagulants

Guidance offered for NVAF patients who temporarily go off anticoagulants due to surgery

Contact: Katie Glenn, kglenn@acc.org, 202-375-6472

WASHINGTON (Jan 09, 2017) -

A new document for the management of patients with irregular heartbeats who are on anticoagulation medications—blood thinners—and need surgery, focuses on how and when to temporarily stop these medications, if a substitute medication should be used, and when it is safe for a patient to go back on blood thinners after surgery. The American College of Cardiology decision pathway document, based on an extensive review of the existing professional literature, is published today in the Journal of the American College of Cardiology.

Certain patients are prescribed anticoagulation medications to help prevent strokes and blood clots. However, if a patient has an irregular heartbeat due to a condition unrelated to a heart valve—which is known as nonvalvular atrial fibrillation—and that patient needs surgery, he or she must usually go off these medications temporarily. This is because the medications, in this setting, could contribute to increased bleeding during the procedure and afterward.

Managing patients during this time period is often challenging and varies among hospitals, practitioners and specialties. Typically, no matter where a patient is being treated, many specialists contribute to the decision-making process.

"All these specialists possess valuable knowledge; however, they have differing perspectives, which can make the decision-making process complex," said John U. Doherty, MD, FACC, chair of the writing committee. "With this new decision pathway, physicians will be able to make better-informed decisions, and this will contribute to improved patient outcomes. In North America alone, more than 250,000 nonvalvular atrial fibrillation patients undergo surgery annually, so this document will impact many people."

The document provides guidance to physicians on:

  • The overall decision to keep a patient chronically on an anticoagulant by examining whether anticoagulation is warranted based on overall thrombotic risk.
  • The decision to take the patient off an anticoagulant temporarily.
  • How to temporarily stop the use of vitamin K antagonists (VKAs) and direct-acting oral anticoagulants (DOACs).
  • Deciding if "bridging" a patient before, during and after surgery is the best choice. "Bridging" is when a doctor temporarily discontinues an oral medication and instead uses another type, such as an injection or an IV drip.
  • Deciding how to bridge before, during and after surgery.
  • Deciding how and when to restart the patient's regular anticoagulant after a surgery.

The American College of Cardiologyis a 52,000-member medical society that is the professional home for the entire cardiovascular care team. The mission of the College is to transform cardiovascular care and to improve heart health. The ACC leads in the formation of health policy, standards and guidelines. The College operates national registries to measure and improve care, offers cardiovascular accreditation to hospitals and institutions, provides professional medical education, disseminates cardiovascular research and bestows credentials upon cardiovascular specialists who meet stringent qualifications. For more, visit acc.org.

The Journal of the American College of Cardiology is the most widely read cardiovascular journal in the world and is the top ranked cardiovascular journal for its scientific impact. JACC is the flagship for a family of journals that publish peer-reviewed research on all aspects of cardiovascular disease. JACC: Cardiovascular Interventions, JACC: Cardiovascular Imaging and JACC: Heart Failure also rank among the top ten cardiovascular journals for impact. JACC: Clinical Electrophysiology and JACC: Basic to Translational Science are the newest journals in the JACC family. Learn more at JACC.org.

###

< Back to Listings